Valiant Pharmaceuticals is a publicly listed company tracked for investment-relevant business developments.
Valiant grew by acquiring off-patent drugs, booking purchase price as acquired R&D/goodwill, then adding back amortization as 'non-cash' to report pro-forma EPS while GAAP showed losses — a business model designed to exploit pro-forma accounting loopholes.